Cargando…

Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests

In antidiabetic drug development, phase I studies usually involve short‐term glucose provocations. Multiple designs are available for these provocations (e.g., meal tolerance tests (MTTs) and graded glucose infusions (GGIs)). With a highly nonlinear, complex system as the glucose homeostasis, the va...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahim, Moustafa M. A., Ghadzi, Siti M. S., Kjellsson, Maria C., Karlsson, Mats O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063744/
https://www.ncbi.nlm.nih.gov/pubmed/29732710
http://dx.doi.org/10.1002/psp4.12302
_version_ 1783342600925741056
author Ibrahim, Moustafa M. A.
Ghadzi, Siti M. S.
Kjellsson, Maria C.
Karlsson, Mats O.
author_facet Ibrahim, Moustafa M. A.
Ghadzi, Siti M. S.
Kjellsson, Maria C.
Karlsson, Mats O.
author_sort Ibrahim, Moustafa M. A.
collection PubMed
description In antidiabetic drug development, phase I studies usually involve short‐term glucose provocations. Multiple designs are available for these provocations (e.g., meal tolerance tests (MTTs) and graded glucose infusions (GGIs)). With a highly nonlinear, complex system as the glucose homeostasis, the various provocations will contribute with different information offering a rich choice. Here, we investigate the most appropriate study design in phase I for several hypothetical mechanisms of action of a study drug. Five drug effects in diabetes therapeutic areas were investigated using six study designs. Power to detect drug effect was assessed using the likelihood ratio test, whereas precision and accuracy of the quantification of drug effect was assessed using stochastic simulation and estimations. An overall summary was developed to aid designing the studies of antihyperglycemic drug development using model‐based analysis. This guidance is to be used when the integrated glucose insulin model is used, involving the investigated drug mechanisms of action.
format Online
Article
Text
id pubmed-6063744
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60637442018-07-31 Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests Ibrahim, Moustafa M. A. Ghadzi, Siti M. S. Kjellsson, Maria C. Karlsson, Mats O. CPT Pharmacometrics Syst Pharmacol Research In antidiabetic drug development, phase I studies usually involve short‐term glucose provocations. Multiple designs are available for these provocations (e.g., meal tolerance tests (MTTs) and graded glucose infusions (GGIs)). With a highly nonlinear, complex system as the glucose homeostasis, the various provocations will contribute with different information offering a rich choice. Here, we investigate the most appropriate study design in phase I for several hypothetical mechanisms of action of a study drug. Five drug effects in diabetes therapeutic areas were investigated using six study designs. Power to detect drug effect was assessed using the likelihood ratio test, whereas precision and accuracy of the quantification of drug effect was assessed using stochastic simulation and estimations. An overall summary was developed to aid designing the studies of antihyperglycemic drug development using model‐based analysis. This guidance is to be used when the integrated glucose insulin model is used, involving the investigated drug mechanisms of action. John Wiley and Sons Inc. 2018-05-06 2018-07 /pmc/articles/PMC6063744/ /pubmed/29732710 http://dx.doi.org/10.1002/psp4.12302 Text en © 2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Ibrahim, Moustafa M. A.
Ghadzi, Siti M. S.
Kjellsson, Maria C.
Karlsson, Mats O.
Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests
title Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests
title_full Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests
title_fullStr Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests
title_full_unstemmed Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests
title_short Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests
title_sort study design selection in early clinical anti‐hyperglycemic drug development: a simulation study of glucose tolerance tests
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063744/
https://www.ncbi.nlm.nih.gov/pubmed/29732710
http://dx.doi.org/10.1002/psp4.12302
work_keys_str_mv AT ibrahimmoustafama studydesignselectioninearlyclinicalantihyperglycemicdrugdevelopmentasimulationstudyofglucosetolerancetests
AT ghadzisitims studydesignselectioninearlyclinicalantihyperglycemicdrugdevelopmentasimulationstudyofglucosetolerancetests
AT kjellssonmariac studydesignselectioninearlyclinicalantihyperglycemicdrugdevelopmentasimulationstudyofglucosetolerancetests
AT karlssonmatso studydesignselectioninearlyclinicalantihyperglycemicdrugdevelopmentasimulationstudyofglucosetolerancetests